Intensified glucose lowering in type 2 diabetes. Reply to Czupryniak L, Szymańska-Garbacz E, Pawłowski M et al. [letter], Aizawa T and Funase Y [letter] and DeVries JH [letter]

Diabetologia

Volumn 54, Issue 3, 2011, Pages 707-708

  Yudkin, J S ^a,b   Richter, B ^c   Gale, E A M ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Heinrich Heine University ^*  (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cardiovascular disease; Glycaemic control; Guidelines; Risk factors; Risk reduction; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; ROSIGLITAZONE;

AGE; BLINDNESS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE DURATION; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; KIDNEY FAILURE; LETTER; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SURVIVAL RATE;

EID: 79953744514     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-2016-1     Document Type: Letter

References (13)

1. Czupryniak L, Szymańska-Garbacz E, Pawłowski M, Saryusz-Wolska M, Loba J (2011) Intensified glucose lowering in type 2 diabetes: time for a bolder reappraisal. Diabetologia. doi:10.1007/s00125-010-2011-6
2. Aizawa T, Funase Y (2011) Intervention at the very early stage of type 2 diabetes. Diabetologia. doi:10.1007/s00125-010-1997-0
3. Yudkin JS, Richter B, Gale EAM (2010) Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia 53:2079-2085
4. Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288-2298, Erratum 52:2470
5. Yudkin JS (1996) Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist. Diabetologia 39:1407-1408
6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected myocardial infarction: ISIS-2. Lancet 332:349-360
7. Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RP, Cohen RM, Goff DC Jr, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER, Action to Control Cardiovascular Risk in Diabetes Investigators (2010) Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD Trial. Diab Care 33:983-990
8. DeVries JH (2011) Intensified glucose lowering in type 2 diabetes: don't throw the baby out with the bathwater. Diabetologia. doi:10.1007/s00125-010- 1991-6
9. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
10. The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572
11. Duckworth W, Abraira C, Moritz T, VADT Investigators et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
12. Yudkin JS, Richter B (2010) Concerns about meta-analysis of glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 152:63
13. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853